[The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
40 patients with benign prostatic hyperplasia (BPH) were treated with the alpha-blocker alfuzosin which was administered per os twice a day in a dose 5 mg. The treatment brought about a decrease of the mean symptom score from 19.6 to 12.2, of quality of life from 5.2 to 2.1, of residual urine from 152 to 82 ml. Mean and maximal urinary flow rates rose by 35 and 45%, respectively. The level of prostate-specific antigen over the treatment course did not change. The findings of the trial evidence for high efficacy of alfuzosin in the treatment of urination disorders in BPH patients.
Mazo
E B
EB
Matushevskiĭ
I A
IA
Nikitin
Iu Iu
IuIu
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D011788:Quality of Life; D011799:Quinazolines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin
Lechenie bol'nykh s dobrokachestvennoĭ giperplazieĭ predstatel'noĭ zhelezy selektivnym al'fa-blokatorom al'fuzozinom.